Abstract
Thirty chronic ambulatory schizophrenic patients whose main psychopathology was characterized by the persistence of negative symptoms, such as emotional withdrawal, depressed mood, motor retardation and blunted affect were included in this project in order to evaluate the therapeutic efficacy of tranylcypromine plus chlorpromazine therapy. The results show that tranylcypromine when added to the usual dose of chlorpromazine, in many instances, induces a definite improvement in these patients' clinical condition, that such treatment is safe and it may be also useful in preventing the occurrence of extra-pyramidal symptoms.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Anden EN (1972) Dopamine turnover in the corpus striatum and limbic system after treatment with neuroleptics and antiacetylcholine drugs. J Pharm Pharmacol 24:905–906
Bailey Sd'A, Bucci L, Gosline E, Kline NS et al. (1959) Comparison of iproniazid with other monoamine oxidase inhibitors including W-1544, JB-516, RO-4-1018 and RO-5-700. Ann NY Acad Sci 80:652–667
Baldessarini R, Tarsy D (1980) Dopamine and pathophysiology of dyskenesia induced by antipsychotic drugs. Ann Rev Neurosci 3:23–41
Birkmayer W (1978) Long-term treatment with 1-deprenyl. J Neural Transm 45:239–244
Blackwell B, Marley E (1964) Interaction between cheese and monoamine oxidase inhibitors. Lancet II:530–531
Bucci L (1967) Monoamine oxidase inhibitors and schizophrenia. Dis Nerv Syst 28:55–59
Bucci L (1968) The psychiatrist and the monoamine oxidase inhibitors. Dis Nerv Syst 29:127–130
Bucci L (1969) The monoamine oxidase inhibitors: the usefulness and their safety. Dis Nerv Syst 30:843–847
Bucci L (1971) The dyskinesia — a new therapeutic approach. Dis Nerv Syst 32:324–327
Carenzi A, Gillin C, Guidotti A, Schwartz M, Wyatt RJ (1953) Dopamine sensitive adenylate cyclase in human caudate nucleus. A study in control subjects and schizophrenic patients. Arch Gen Psychiatry 32:1056–1059
Cole JO, Jone RT, Klermann GL (1961) Drugs therapy. In: Progress in neurology and psychiatry, vol. 16. pp 539–574
Crow TJ (1980) Molecular pathology of schizophrenia: more than one process? Br Med J 12:66–68
Deniker P (1962) Monoamines, médicaments psychtropiques et nosographie psychiatriques. In: de Ajuriagverra J (ed) Monoamines et system nerveux centrale. Masson, Paris, pp 215–232
Hornykiewicz O (1973) Parkinson's disease: From brain homogenates to treatment. Fed Proc 32:183–190
Johnson DAW (1981a) Oral versus depot medication in schizophrenia. Acta Psychiatr Scand 63 (Suppl 291):56–64
Johnson DAW (1981b) Studies of depressive symptoms in schizophrenia. The prevalence of depression and its possible causes. Br J Psychiatry 139:89–101
Kielholz P, Labhardt F (1962) Déductions tirées de nos connaissances sur les inhibiteurs de MAO par rapport à la classification classiques des psychoses. In: de Ajuriagverra J (ed) Monoamine et system nerveux centrale. Masson Paris, pp 233–238
Knoll J (1983) Deprenyl (Selegiline): The history of its development and pharmacological action. Acta Neurol Scand (Supplement 95):57–94
Memo M, Kleiman JE, Hanbauer I (1983) Coupling of dopamine D1 recognition sites with adenylate cyclase in nuclei accumbens and caudate of schizophrenia. Science 121:1304–1307
MacLean R, Nicholson WJ, Pare CMB et al. (1965) Effects of monoamine oxidase inhibitors on the concentration of 5-hydroxytryptamine in the human brain. Lancet II:204–208
Overall JE, Gorham DR (1962) The brief psychiatric rating scale. Psychol Rep 10:799–912
Pare CMB (1965) Some clinical aspects of antidepressant drugs. In: Marks J, Pare CMB (eds) The scientific basis of drug therapy in psychiatry. Pergamon, NY, pp 103–113
Parkes CM, Broan GW, Monk EM (1962) The general practitioner and the schizophrenic patients. Br Med J 1:972–973
Snyder SH (1982) Neurotransmitters and C.N.S. diseases: Schizophrenia. Lancet II:970–973
Spitzer RL, Edincott J, Robins E (1978) Research Diagnostic Criteria. Arch Gen Psychiatry 35:773–782
Tyrer P (1973) Are monoamine oxidase inhibitors antidepressant? Proc Soc Med 66:950–951
Tyrer P (1976) Toward rational therapy with monoamine oxidase inhibitors. Br J Psychiatry 128:354–360
Van Kammen DP (1979) The dopamine hypothesis of schizophrenia revisited. Psychoneuroendocrinology 4:37–46
Van Putten T, May PRA (1978) Akinetic depression. Arch Gen Psychiatry 35:1101–1107
Werner G (1962) Clinical pharmacology of central stimulant and antidepressant drugs. Clin Pharmacol Ther 3:59–96
Worms P (1983) Behavioral pharmacology of benzamides as compared to standard neuroleptics. In: Rotrosen J, Stanley M (eds) The benzamides: pharmacology, neurobiology and clinical aspects. Raven, New York, pp 7–16
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bucci, L. The negative symptoms of schizophrenia and the monoamine oxidase inhibitors. Psychopharmacologia 91, 104–108 (1987). https://doi.org/10.1007/BF00690936
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00690936